{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-032706","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.599067+00:00","generated_at":"2026-05-16T05:48:45.147268+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Perspective Therapeutics updates corporate presentation with estimated cash balance and pipeline milestones","bullets":["Estimated cash, cash equivalents and short-term investments as of Dec 31, 2025 disclosed (amount not specified in filing).","Phase 1/2 data expected across all three clinical programs during 2026.","VMT-α-NET shows durable disease control and best-in-class safety profile in neuroendocrine tumors.","VMT01 exhibits preliminary anti-tumor activity at lower doses in melanoma.","PSV359 targeting FAP-α for solid tumors is ongoing in Phase 1/2a trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-032706","json":"https://secwatch.observer/filing/0001193125-26-032706.json","markdown":"https://secwatch.observer/filing/0001193125-26-032706.md","text":"https://secwatch.observer/filing/0001193125-26-032706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526032706/0001193125-26-032706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526032706/catx-20260202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:48:45.147268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}